SOLID TUMORS

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This early-phase trial tests a new type of immunotherapy called CAR T cells that are designed to recognize and attack cancer cells with a protein called CD70. The study includes 88 patients with lymphoma, myeloma, or certain solid tumors (like kidney cancer or sarcoma) that have …

This early-phase study tests an oral drug called SNH-118110 in 240 adults with advanced solid tumors that have a specific genetic change (RET). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have tried other treatm…

This early-phase study tests a new treatment using specially engineered natural killer (NK) cells boosted with IL-15 to fight advanced solid tumors that have not responded to standard therapies. About 12 adults aged 18-70 with metastatic or recurrent cancers like breast, liver, o…

This early-phase study tests a new drug (BI 1831169) combined with an existing immunotherapy (anti-PD1 antibody) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find the highest safe dose of the combination …

This study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 326 adults aged 18 to 75 with good overall health will take …

This study tests whether combining lenvatinib (a targeted therapy) with a PD-1 inhibitor (immunotherapy) can shrink or stop advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers (like esophageal, head and neck, …

This early-phase study tests a new combination of two drugs, risvutatug rezetecan and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find safe dose levels, check for side effects, and see if the combination can shrink tumors. T…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…

This study tests a new approach for people with solid tumors (like breast cancer) that have spread to the brain. The drugs used are called theranostic agents—they can both find cancer cells and deliver radiation to kill them. The trial will first check if the drug reaches the bra…

This early-phase study tests a personalized cell therapy for people with extensive-stage small cell lung cancer or similar neuroendocrine cancers that came back after standard treatment. Researchers take a patient's own immune cells, modify them to recognize a protein called B7-H…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to stop antibiotics early or continue standard treatment. The goal is to see if early stoppi…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This study tests a drug called romiplostim N01 in 60 adults with solid tumors who have low platelets after radiation combined with other cancer treatments. The goal is to see if the drug can safely raise platelet counts and reduce the need for transfusions. It is a phase 2 trial,…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This study will test a new imaging agent called 68Ga-B6FA-01, which targets two different markers on cancer cells and their surroundings. The goal is to see if this probe can improve PET/CT scans for diagnosing and staging solid tumors. About 100 adults with newly diagnosed or re…

This early study will test a new type of PET scan that uses two targets (FAPI and PSMA) at once to find and stage solid tumors like prostate, liver, ovarian, and endometrial cancers. About 20 adults with suspected or confirmed tumors will get this new scan, and doctors will compa…